Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Exai Bio

Exai Bio Appoints Oncology Leader and Former American Cancer Society CEO, Karen E. Knudsen, MBA, PhD, to its Board of Directors
From Exai Bio
Via Business Wire
Exai Bio Announces Publication in Nature Communications Highlighting its Generative AI Liquid Biopsy Platform
From Exai Bio
Via Business Wire
Exai Bio Appoints Dave Daly as Chief Executive Officer
From Exai Bio
Via Business Wire
Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting
From Exai Bio
Via Business Wire
Exai Bio’s RNA- and AI-based Liquid Biopsy Platform Detects Early Stage Breast Cancer with High Accuracy, Overcoming Many Limitations of DNA-based Approaches
From Exai Bio
Via Business Wire
Exai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer
From Exai Bio
Via Business Wire
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
From Exai Bio
Via Business Wire
Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting
From Exai Bio
Via Business Wire
Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer
From Exai Bio
Via Business Wire
Exai Bio Announces Appointments of Emi Zychlinsky and Seema Singh Bhan to its Executive Leadership Team
From Exai Bio
Via Business Wire
Exai Bio’s RNA-based Liquid Biopsy Platform Delivers Promising Data on Detecting Breast Cancer at its Earliest Stages
From Exai Bio
Via Business Wire
Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer
From Exai Bio
Via Business Wire
Exai Bio Demonstrates Its Unique RNA-based Liquid Biopsy Strategy for Early Detection and Monitoring of Multiple Cancers
From Exai Bio
Via Business Wire
Exai Bio Secures $67.5 Million Series A Financing to Advance Next-Generation, RNA-Based Liquid Biopsy Platform for Early Cancer Detection
From Exai Bio
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.